The genetic mutations that are commonly associated with pancreatic cancer are mutations of the Kirsten rat sarcoma viral oncogene homolog (KRAS), tumor protein 53 (TP53), mothers against decapentaplegic homolog 4 (SMAD4), also known as depleted in pancreatic cancer 4 (DPC4), and cyclin-dependent kinase inhibitor 2 (CDKN2) genes—none of which can be remedied through currently available treatment methods [4,6]. The gene discussed is SMAD4; the disease is pancreatic neoplasm.